BIOCON BIOLOGICS UK PLC

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -29.4%

  £393,141,213 → £277,417,209

• Cash

  +153.7%

  £2,315,915 → £5,875,009

• Net assets

  -2.1%

  £1,020,755,775 → £999,572,400

• Employees

  —

  Not reported

• Operating profit

  +55%

  -£56,720,490 → -£25,533,378

• Profit before tax

  -163.8%

  -£25,409,285 → -£67,021,754

• Wages

  +290.2%

  £358,077 → £1,397,174

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. BIOCON BIOLOGICS UK PLC 2025-10-29 → present
2. BIOCON BIOLOGICS UK LIMITED 2025-10-21 → 2025-10-29
3. BIOSIMILARS NEWCO LIMITED 2022-07-27 → 2025-10-21

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

KNAV Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors believe that the Company's assumption of going concern is appropriate based on their assessment.”

Significant events

• “The Group marked one-year milestone of completing the integration of the acquired biosimilar business from Viatris Inc.”
• “The directors of the Company through a written resolution dated 31 March 2025 have approved acquisition of the business and assets from Biocon Biologics UK Limited relating to biosimilar business, including inter alia, the development, manufacturing and/or commercialization of certain products and compounds pursuant to the terms of the Business Transfer Agreement with effect from 1 April 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

3

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.